Homologous Recombination Repair Deficiency and Implications for Tumor Immunogenicity.

van Wilpe, Sandra; Tolmeijer, Sofie H; Koornstra, Rutger H T; de Vries, I Jolanda M; Gerritsen, Winald R; Ligtenberg, Marjolijn; Mehra, Niven

van Wilpe, Sandra; Tolmeijer, Sofie H; Koornstra, Rutger H T; de Vries, I Jolanda M; Gerritsen, Winald R; Ligtenberg, Marjolijn; Mehra, Niven.

Afiliación

van Wilpe S; Department of Medical Oncology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.
Tolmeijer SH; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.
Koornstra RHT; Department of Medical Oncology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.
de Vries IJM; Department of Medical Oncology, Rijnstate Hospital, 6815 DA Arnhem, The Netherlands.
Gerritsen WR; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.
Ligtenberg M; Department of Medical Oncology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.
Mehra N; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.

Cancers (Basel) ; 13(9)2021 May 07.

Article en En | MEDLINE | ID: mdl-34067105

Palabras clave

cancer; homologous recombination repair deficiency; immune checkpoint inhibitors

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Cancers (Basel) Año: 2021 Tipo del documento: Article País de afiliación: Países Bajos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google